Report Library
All Reports
Datamonitor Malignant Melanoma Pricing and Reimbursement
February 29, 2016
Datamonitor's independent research and analysis
provides extensive coverage of major disease areas, companies and strategic issues,
giving you the perspective to identify opportunities and threats arising from shifting market dynamics and the insights to
respond with faster, more effective decision-making. This strategy report focuses on Malignant Melanoma Pricing and Reimbursement
including how immunotherapies are changing melanoma treatment paradigms with market conext in the US, Japan, and five major EU
markets.
Highlights
For more information on Datamonitor strategy reports, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
Highlights
- Market entry of new drugs will dramatically increase the budget impact of melanoma treatments.
- Overview of marketed malignant melanoma products in the US, Japan, and five major EU markets.
- In Japanese markets, successful pricing outcomes hinge on receipt of a pricing premium for melanoma drugs.
For more information on Datamonitor strategy reports, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: | Melanoma |
Additional Resources: